SPY342.73-0.65 -0.19%
DIA281.97-0.98 -0.35%
IXIC11,484.69-31.80 -0.28%

Morgan Stanley Maintains Overweight on Blueprint Medicines, Raises Price Target to $100

Morgan Stanley maintains Blueprint Medicines (NASDAQ:BPMC) with a Overweight and raises the price target from $92 to $100.

· 10/13/2020 08:32
Morgan Stanley maintains Blueprint Medicines (NASDAQ:BPMC) with a Overweight and raises the price target from $92 to $100.